|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM301738807 |
| 003 |
DE-627 |
| 005 |
20240722232035.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2019 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.201903637
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1478.xml
|
| 035 |
|
|
|a (DE-627)NLM301738807
|
| 035 |
|
|
|a (NLM)31566258
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Kim, Byungji
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Rekindling RNAi Therapy
|b Materials Design Requirements for In Vivo siRNA Delivery
|
| 264 |
|
1 |
|c 2019
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 10.04.2020
|
| 500 |
|
|
|a Date Revised 22.07.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
|
| 520 |
|
|
|a With the recent FDA approval of the first siRNA-derived therapeutic, RNA interference (RNAi)-mediated gene therapy is undergoing a transition from research to the clinical space. The primary obstacle to realization of RNAi therapy has been the delivery of oligonucleotide payloads. Therefore, the main aims is to identify and describe key design features needed for nanoscale vehicles to achieve effective delivery of siRNA-mediated gene silencing agents in vivo. The problem is broken into three elements: 1) protection of siRNA from degradation and clearance; 2) selective homing to target cell types; and 3) cytoplasmic release of the siRNA payload by escaping or bypassing endocytic uptake. The in vitro and in vivo gene silencing efficiency values that have been reported in publications over the past decade are quantitatively summarized by material type (lipid, polymer, metal, mesoporous silica, and porous silicon), and the overall trends in research publication and in clinical translation are discussed to reflect on the direction of the RNAi therapeutics field
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a RNA interference
|
| 650 |
|
4 |
|a drug delivery
|
| 650 |
|
4 |
|a gene therapy
|
| 650 |
|
4 |
|a nanoparticles
|
| 650 |
|
4 |
|a siRNA
|
| 650 |
|
7 |
|a Drug Carriers
|2 NLM
|
| 650 |
|
7 |
|a RNA, Small Interfering
|2 NLM
|
| 700 |
1 |
|
|a Park, Ji-Ho
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sailor, Michael J
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 31(2019), 49 vom: 30. Dez., Seite e1903637
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:31
|g year:2019
|g number:49
|g day:30
|g month:12
|g pages:e1903637
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.201903637
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 31
|j 2019
|e 49
|b 30
|c 12
|h e1903637
|